Healthcare / BiotechnologyNasdaqGM
$3.96
-0.14 (-3.41%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-364.0M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-56.0%
↓Gross Margin
34.3%
↓Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2008–2025 · 17 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-127.6%
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $263.5M · net income $-391.0M · FCF $-336.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||
| Revenue | $263.5M | $263.5M | $164.1M | $1.2M | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Net Income | $-391.0M | $-391.0M | $-372.2M | $-444.0M | $-395.9M | $-342.3M | $-259.6M | $-197.6M | $-123.6M | $-92.1M | $-52.9M | $-27.7M | $-12.0M | $-25.4M | $-3.3M | $-25.7M | $-1.6M | $-15772.00 | $-58716.00 |
| EBITDA | $-350.9M | $-350.9M | $-347.2M | $-427.4M | $-377.7M | $-339.6M | $-260.8M | $-205.7M | $-127.3M | $-91.9M | $-52.7M | $-26.9M | $-12.0M | $-22.6M | $-8.1M | $-21.2M | $-756816.00 | $-14440.00 | — |
| EPS | -1.09 | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | -1.88 | -1.59 | — | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 34.3% | 34.3% | 43.2% | 13.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -151.1% | -151.1% | -240.9% | -38735.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -148.4% | -148.4% | -226.8% | -37345.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||
| Debt/Equity | 0.07 | 0.07 | 0.08 | 0.13 | 0.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 3.60 | 3.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||
| Free Cash Flow | $-336.2M | $-336.2M | $-364.0M | $-384.1M | $-313.2M | $-265.5M | $-251.9M | $-165.8M | $-102.4M | $-79.7M | $-34.2M | $-19.5M | $7.0M | $-12.8M | $-2.2M | $-6.2M | $-620805.00 | $-14448.00 | — |
| Returns | |||||||||||||||||||
| ROE | -56.0% | -56.0% | -52.4% | -76.0% | -79.2% | -55.1% | -39.5% | -66.1% | -26.5% | -63.3% | -31.7% | -26.6% | -26.8% | -144.2% | 29.2% | 201.0% | -252.0% | 116.9% | -2570.8% |
| Valuation | |||||||||||||||||||
| P/B | 2.03 | 2.03 | 3.12 | 3.41 | 2.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||
| Revenue Growth | 60.6% | 60.6% | 13699.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | 14.8% | 14.8% | 32.3% | 24.1% | — | -18.6% | -18.2% | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+126.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.28 → -1.09
Residual
+126.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.